SELENOW and metastatic malignant neoplasm: As SELENOW is differentially regulated under physiological and pathological conditions, further studies are needed to identify the role of SELENOW in various bone defects, including postmenopausal osteoporosis [34], arthritis-causing bone deformity [35], and bone-metastatic cancer-mediated osteoporosis [36].